What Does the Historical and Current Emphysema Treatment Market Size Trend Indicate?
The emphysema treatment market has seen considerable growth due to a variety of factors.
•The market size for treating emphysema has shown robust growth in the last few years. It is expected to expand from a value of $5.15 billion in 2024 to $5.43 billion in 2025, with a compound annual growth rate (CAGR) of 5.6%.
This past growth has been largely due to factors such as the effects of the smoking epidemic, progress in medicinal treatments, the implementation of pulmonary rehabilitation programs, increased awareness, education and enhancements in diagnostic methods.
How Will the Emphysema Treatment Market Size Evolve over the Forecast Period?
The emphysema treatment market is expected to maintain its strong growth trajectory in upcoming years.
• Forecasted robust expansion is anticipated in the emphysema treatment market in the coming years, with expectations to reach $7.4 billion by 2029, with an annual growth rate (CAGR) of 8.0%.
The forthcoming growth can be credited to factors such as the aging population, tailored treatment methods, wider availability of therapies, a concentration on symptom control, and partnerships in healthcare models. Key trends for the forecast period incorporate the investigation into gene therapies, enhancing patient knowledge and autonomy, amalgamation of artificial intelligence (AI), better treatment accessibility, and the development of prolonged medication schemes.
Which Factors Are Boosting Growth In The Emphysema Treatment Market?
The escalation in instances of chronic obstructive pulmonary disease (COPD) is speculated to stimulate the expansion of the emphysema treatment market in the future. COPD comprises a collection of illnesses that cause disruption in the airflow and respiratory problems, including chronic bronchitis and emphysema. Therapies for emphysema are crucial in curbing further development of COPD as they concentrate on treating symptoms, restoring lung function, and stalling the disease's progression. For example, reporting in June 2024, the Australian Institute of Health and Welfare (AIHW), a domestic agency, estimated that in 2022, around 638,000 people in Australia, or 2.5% of the population, were affected by COPD. By 2023, the prevalence of COPD had increased to 3.6% of the overall disease burden, accounting for half of the total respiratory conditions burden. Moreover, in 2022, COPD was the core reason for 7,691 deaths, translating to 29.6 deaths per 100,000 people and making up 4.0% of all mortalities in the region. This increase in the presence of chronic obstructive pulmonary disease (COPD) incidents therefore fuels the emphysema treatment market.
What Key Areas Define The Segmentation Of The Global Emphysema Treatment Market?
The emphysema treatment market covered in this report is segmented –
1) By Treatment: Smoking Cessation, Bronchodilators, Steroids, Leukotriene Modifiers, Supplemental Oxygen, Antibiotics, Gene Therapy, Surgery Transplant, Other Treatments
2) By Distribution Channel: Online Providers, Drug Stores and Retail Pharmacies, Hospital Pharmacies
3) By End-User: Clinics, Surgical Centre, Other End-Users
Subsegments:
1) By Smoking Cessation: Nicotine Replacement Therapy (NRT), Prescription Medications, Behavioral Therapy Programs
2) By Bronchodilators: Short-Acting Beta-Agonists (SABAs), Long-Acting Beta-Agonists (LABAs), Anticholinergics
3) By Steroids: Inhaled Corticosteroids (ICS), Oral Corticosteroids, Combination Inhalers
4) By Leukotriene Modifiers: Montelukast, Zafirlukast
5) By Supplemental Oxygen: Portable Oxygen Concentrators, Continuous Flow Oxygen Systems, Pulse Dose Oxygen Systems
6) By Antibiotics: Macrolides, Fluoroquinolones, Tetracyclines
7) By Gene Therapy: Gene Replacement Therapy, Antisense Oligonucleotides
8) By Surgery Transplant: Lung Volume Reduction Surgery (LVRS), Lung Transplantation
9) By Other Treatments: Pulmonary Rehabilitation Programs, Nutritional Support, Palliative Care
Pre-Book The Emphysema Treatment Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are Emerging Trends Reshaping The Dynamics Of The Emphysema Treatment Market?
Major firms involved in the emphysema industry are innovating minimally invasive procedures for patients with emphysema to attain a competitive advantage. Minimally invasive procedures are medical operations or surgical methods that cause minimal disruption to the normal human structures. For instance, Adena Health System, an American healthcare company, introduced the Zephyr Valve surgery in January 2022. This minimally invasive technique presents an alternative to traditional lung volume reduction surgery for individuals suffering from lung hyperinflation - a frequent condition in emphysema and COPD. This revolutionary method involves the insertion of tiny, one-way Zephyr Valves into the lung airways using a bronchoscope. These valves aid in the expulsion of trapped air, blocking further build-up, and enabling healthier lung sections to enlarge, subsequently enhancing respiration.
Who Are the Key Players in the Emphysema Treatment Market?
Major companies operating in the emphysema treatment market include:
• AstraZeneca PLC
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• GlaxoSmithKline PLC
• Hikma Pharmaceuticals PLC
• Boehringer Ingelheim GmbH
• Mylan N.V.
• Pfizer Inc.
• Orion Oyj
• Verona Pharma PLC
• Pulmonx Corporation
• Emphasys Medical Inc.
• Halozyme Therapeutics Inc.
• Mariposa Health Limited
• Uptake Technologies Inc.
• Respinova Ltd
• Gala Therapeutics Inc.
• Pulmatrix Inc.
• Broncus Medical Inc.
• Holaira Inc.
• PneumRx Inc.
• Spiration Inc.
• Aeris Therapeutics Inc.
• CSA Medical Inc.
• Olympus Corporation
What Is The Most Dominant Region In The Emphysema Treatment Market?
North America was the largest region in the emphysema treatment market in 2024. The regions covered in the emphysema treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
